Walleye Capital
SGMO

Walleye Capital’s SANGAMO THERAPEUTICS INC SGMO Stock Holding History

Walleye Capital’s Portfolio SGMO Stock Details SGMO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-54,100
Closed -$583K – 2233
2019
Q2 		$583K Sell
54,100
-23,000
-30% -$245K 0.06% 436
2019
Q1 		$736K Buy
+77,100
New +$787K 0.12% 248

Other funds holding SGMO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Walleye Capital's SGMO Position: Q1 2025 in Review

Walleye Capital sold out of SANGAMO THERAPEUTICS INC (SGMO) in Q1 2025, closing a stake of 13,712 shares — an estimated $14K sold.

Walleye Capital first reported a position in SGMO in Q1 2019 and held it in 10 quarters. The position peaked at $488K in Q1 2022. 122 funds tracked by Wall St. Rank hold SGMO as of Q1 2025.

  • Walleye Capital reported no remaining SANGAMO THERAPEUTICS INC position as of Q1 2025 after selling out during the quarter.
  • Walleye Capital sold 13,712 SANGAMO THERAPEUTICS INC shares in Q1 2025, an estimated $14K.
  • Walleye Capital first reported a position in SANGAMO THERAPEUTICS INC in Q1 2019 and held it in 10 quarters.
  • Walleye Capital's SANGAMO THERAPEUTICS INC position peaked at $488K in Q1 2022.
  • 122 funds tracked by Wall St. Rank held SANGAMO THERAPEUTICS INC as of Q1 2025.

Based on Walleye Capital's 13F filing for Q1 2025, filed 14 May 2025.